EVVIVAX
Evvivax is a biotechnology spin-off focused on veterinary cancer immunotherapy and veterinary vaccines. The company develops nucleic-acid vaccines (plasmid, viral vector and PCR-produced linear DNA constructs), delivery methods based on in vivo electroporation, conducts preclinical and veterinary clinical trials, and performs process development and industrial-scale production activities with GMP-like workflows to support translation and regulatory submissions for veterinary biologics. Evvivax collaborates with academic partners and external DNA manufacturing providers. Headquartered in Rome, Italy.
Industries
Nr. of Employees
small (1-50)
EVVIVAX
Via Castel Romano, 100, Rome 00128, Italy
Patents
Consensus sequence of the antigen telomerase and the use thereof in preventive and therapeutic vaccination
US-12622955-B2
View Details
Consensus sequence of the antigen telomerase and the use thereof in preventive and therapeutic vaccination
US-12622955-B2
View DetailsProducts
Therapeutic telomerase-targeting vaccine program for companion animals
A therapeutic vaccine program targeting telomerase to stimulate anti-tumor immunity and evaluate effects on tumor control and survival in dogs and cats; clinical data include prior canine studies showing extended survival when combined with standard care.
Therapeutic HER2/neu-targeting vaccine program for companion animals
A therapeutic vaccine program targeting HER2/neu (ErbB) to stimulate cellular and humoral anti-tumor responses and assess clinical outcomes in dogs and cats with HER2/neu-expressing tumors.
Therapeutic telomerase-targeting vaccine program for companion animals
A therapeutic vaccine program targeting telomerase to stimulate anti-tumor immunity and evaluate effects on tumor control and survival in dogs and cats; clinical data include prior canine studies showing extended survival when combined with standard care.
Therapeutic HER2/neu-targeting vaccine program for companion animals
A therapeutic vaccine program targeting HER2/neu (ErbB) to stimulate cellular and humoral anti-tumor responses and assess clinical outcomes in dogs and cats with HER2/neu-expressing tumors.
Services
Design and conduct of veterinary oncology and infectious disease clinical trials in partnership with academic and clinical sites to evaluate safety, immunogenicity and preliminary efficacy of vaccine candidates; includes on-site trial supervision and laboratory endpoints such as neutralization and T-cell assays.
Process development for viral vector and DNA vaccine manufacturing, implementation of GMP-like production workflows, development of analytical quality assays, and support for lyophilized vaccine formulation enabling ambient stability for distributed supply.
Design and conduct of veterinary oncology and infectious disease clinical trials in partnership with academic and clinical sites to evaluate safety, immunogenicity and preliminary efficacy of vaccine candidates; includes on-site trial supervision and laboratory endpoints such as neutralization and T-cell assays.
Process development for viral vector and DNA vaccine manufacturing, implementation of GMP-like production workflows, development of analytical quality assays, and support for lyophilized vaccine formulation enabling ambient stability for distributed supply.
Expertise Areas
- Veterinary cancer immunotherapy
- Nucleic-acid vaccine development (plasmid, viral vector, PCR-produced linear DNA)
- In vivo electroporation-based gene delivery
- Electrochemotherapy
Key Technologies
- Plasmid DNA vaccine platforms
- Viral vector vaccine platforms (adenoviral and related vectors)
- PCR-amplified linear DNA constructs (cell-free linear DNA)
- In vivo electroporation / gene electrotransfer
News & Updates
Publication of a preclinical study showing PCR-produced linear DNA vaccines elicited strong antigen-specific immune and antitumoral responses in mouse cancer models, including comparison to plasmid DNA and enhanced responses when combined with immune checkpoint inhibitors.
Report of an in vitro neutralization study showing all 11 vaccinated domestic felines produced neutralizing antibody titers against multiple SARS-CoV-2 variants; cohort showed tolerability and robust neutralizing responses after a single prime dose with follow-up booster data pending.
Preliminary Phase I clinical results showing the PCR-produced linear DNA vaccine candidate was well tolerated in a cohort of 11 cats and elicited high neutralizing antibody titers after a single prime dose; trial conducted with intramuscular administration via gene electrotransfer and planned booster evaluation.
Preclinical in vivo studies demonstrated tumor reduction using PCR-produced linear DNA vaccine constructs in animal cancer models.
Company scientists presented preclinical and translational vaccine data at international veterinary vaccine and cancer meetings.
Publication of a preclinical study showing PCR-produced linear DNA vaccines elicited strong antigen-specific immune and antitumoral responses in mouse cancer models, including comparison to plasmid DNA and enhanced responses when combined with immune checkpoint inhibitors.
Report of an in vitro neutralization study showing all 11 vaccinated domestic felines produced neutralizing antibody titers against multiple SARS-CoV-2 variants; cohort showed tolerability and robust neutralizing responses after a single prime dose with follow-up booster data pending.
Preliminary Phase I clinical results showing the PCR-produced linear DNA vaccine candidate was well tolerated in a cohort of 11 cats and elicited high neutralizing antibody titers after a single prime dose; trial conducted with intramuscular administration via gene electrotransfer and planned booster evaluation.
Preclinical in vivo studies demonstrated tumor reduction using PCR-produced linear DNA vaccine constructs in animal cancer models.
Company scientists presented preclinical and translational vaccine data at international veterinary vaccine and cancer meetings.